20 November 2017
News and Views
Links and Services
The latest issue of the Annals of Internal Medicine reports that KRAS mutations increase treatment failure of anti–epidermal growth factor receptor in advanced colorectal cancer.
KRAS mutations have been extensively investigated as predictive biomarkers for treatment
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors